William Blair Initiates Coverage on IDEAYA Biosciences With Outperform Rating
IDEAYA Biosciences has an average rating of buy and mean price target of $53.54, according to analysts polled by FactSet.
Model output · Signal date 2026-10-16
Ideaya Biosciences, Inc. (IDYA) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Top 35%
of 5184 stocks scored
Rank correlation · 90D
30.0%
Spearman, 357 dates
Market Cap
$3.17B
mid-cap · #60 of 60 peers
Summary
Ideaya Biosciences, Inc. (IDYA) stock forecast summary
Our AI ranks Ideaya Biosciences, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Ideaya Biosciences, Inc. is a mid-cap company with a market capitalization of $3.17B. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For IDYA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 30.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 17.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, IDYA included.
Follow IDYA freePrice
IDYA price chart and AI forecast
Cross-section · 2026-10-16
How IDYA ranks among 5184 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Ideaya Biosciences, Inc. (IDYA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | IDYA | Rank |
|---|---|---|
| Market Cap | $3.17B | 60/60 |
| P/B Ratio | 2.64x | 38/42 |
| EPS | $-2.73 | – |
| Book Value/Share | $12.43 | – |
| Revenue/Share | $2.43 | – |
| FCF/Share | $-1.18 | – |
Profitability & Margins
| Metric | IDYA | Rank |
|---|---|---|
| ROE | -14.6% | 25/38 |
| ROA | -13.4% | 29/43 |
| ROIC | -17.7% | 31/46 |
| Operating Margin | -92.7% | 34/39 |
| Net Margin | -74.8% | 27/35 |
| EBT Margin | -92.7% | 40/46 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | IDYA | Rank |
|---|---|---|
| Current Ratio | 10.45x | 12/59 |
| D/E Ratio | 0.09x | 39/48 |
| Financial Leverage | 1.09x | 40/48 |
| Interest Coverage | 6551.7x | 1/36 |
| Working Capital | $781M | 35/59 |
Cash Flow
| Metric | IDYA | Rank |
|---|---|---|
| Operating Cash Flow | -$112M | 45/59 |
| Free Cash Flow | -$114M | 38/50 |
| Capital Spending | -$2M | 15/50 |
| FCF/Sales | -48.6% | 37/42 |
| CapEx/Sales | 0.9% | 30/42 |
Operational Efficiency
| Metric | IDYA | Rank |
|---|---|---|
| Asset Turnover | 0.18x | 35/40 |
| Fixed Assets Turnover | 28.3x | 12/41 |
Income Statement
| Metric | IDYA | Rank |
|---|---|---|
| Total Revenue | $234M | 43/46 |
| Operating Income | -$217M | 36/51 |
| Net Income | -$175M | 28/46 |
| R&D Expense | $374M | 35/58 |
Dividend & Shareholder Information
| Metric | IDYA | Rank |
|---|---|---|
| Shares Outstanding | 96M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $864M | 65.9% of assets |
| Cash & Short-term Investments | $273M | 20.8% of assets |
| Total Liabilities | $111M | 8.4% of assets |
| Short-term Debt | $52M | 4.0% of assets |
Quarterly Financial Reports
IDYA quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Ideaya Biosciences, Inc. (IDYA) industry peers
Companies classified under the same SEC industry code as Ideaya Biosciences, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| IDYA Ideaya Biosciences, Inc. | ▲ | $3.17B |
| LLY Eli Lilly & Co | ▶ | $1.18T |
| JNJ Johnson & Johnson | ▼ | $615.87B |
| ABBV Abbvie Inc. | ▶ | $504.37B |
| MRK Merck & Co., Inc. | ▲ | $360.08B |
| NVS Novartis Ag | ▼ | $287.41B |
| AZN Astrazeneca Plc | ▼ | $256.39B |
| ABT Abbott Laboratories | ▼ | $182.39B |
| NVO Novo Nordisk A S | ▼ | $172.56B |
| PFE Pfizer Inc | ▶ | $168.60B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▶ | $126.66B |
| BMY Bristol Myers Squibb Co | ▶ | $122.05B |
| GSK Gsk Plc | ▼ | $100.46B |
| SNY Sanofi | ▼ | $100.12B |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $81.76B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $61.45B |
| TEVA Teva Pharmaceutical Industries Ltd | ▼ | $48.36B |
| ONC Beone Medicines Ltd. | ▲ | $41.96B |
| ZTS Zoetis Inc. | ▼ | $32.80B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.02B |
| RPRX Royalty Pharma Plc | ▶ | $26.88B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.22B |
| GMAB Genmab A/S | ▲ | $23.80B |
| UTHR United Therapeutics Corp | ▶ | $22.87B |
| VTRS Viatris Inc | ▼ | $21.43B |
| INSM Insmed Inc | ▶ | $21.02B |
| ASND Ascendis Pharma A/S | ▲ | $14.85B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.65B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.98B |
| CORT Corcept Therapeutics Inc | ▲ | $11.91B |
| ELAN Elanco Animal Health Inc | ▼ | $11.77B |
| SMMT Summit Therapeutics Inc. | ▶ | $11.67B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.91B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.58B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.39B |
| CYTK Cytokinetics Inc | ▲ | $8.61B |
| TGTX Tg Therapeutics, Inc. | ▲ | $8.56B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.33B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.23B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $7.90B |
| ABVX Abivax S.A. | ▼ | $7.74B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.14B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.05B |
| ALKS Alkermes Plc. | ▲ | $6.92B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.75B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▶ | $6.13B |
| AMRX Amneal Pharmaceuticals, Inc. | ▲ | $6.13B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▲ | $5.93B |
| LGND Ligand Pharmaceuticals Inc | ▶ | $5.89B |
| BLTE Belite Bio, Inc | ▲ | $5.62B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.20B |
| COGT Cogent Biosciences, Inc. | ▶ | $5.12B |
| PTCT Ptc Therapeutics, Inc. | ▲ | $4.94B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $4.76B |
| ERAS Erasca, Inc. | ▲ | $4.68B |
| MANE Veradermics, Inc | ▲ | $4.55B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.44B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.04B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.03B |
| INDV Indivior Pharmaceuticals, Inc. | ▶ | $3.83B |
Where IDYA sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Ideaya Biosciences, Inc. (IDYA) stock news
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC
On February 25, 2026, IDEAYA Biosciences, Inc. (NASDAQ:IDYA) announced that the first patient has been enrolled in its Phase 1 dose escalation and expansion trial evaluating IDE034, an investigational ...
FAQ
Ideaya Biosciences, Inc. (IDYA) stock forecast FAQ
What is the Ideaya Biosciences, Inc. (IDYA) stock forecast?
Our AI ranks Ideaya Biosciences, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Ideaya Biosciences, Inc. stock predictions?
For IDYA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 30.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 17.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Ideaya Biosciences, Inc. forecasts updated?
Ideaya Biosciences, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Ideaya Biosciences, Inc.'s industry peers?
60 issuers in our coverage, IDYA included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.